10 Einträge gefunden

1. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

   1. Leutz, A
   2. Pinter, A
   3. Thaçi, D
   4. Augustin, M
   5. Schuster, C
   6. Fotiou, K
   7. Hundemer, H P

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)

   1. Gordon, K B
   2. Warren, R B
   3. Gottlieb, A B
   4. Blauvelt, A
   5. Thaçi, D
   6. Leonardi, C
   7. Poulin, Y

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study

   1. Thaçi, D
   2. Körber, A
   3. von Kiedrowski, R
   4. Bachhuber, T
   5. Melzer, N
   6. Kasparek, T
   7. Duetting, E

   2020 - Forschungsinformationssystem des UKE
4. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

   1. Reich, K
   2. Augustin, M
   3. Thaçi, D
   4. Pinter, A
   5. Leutz, A
   6. Henneges, C
   7. Schneider, E

   2020 - Forschungsinformationssystem des UKE
5. Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis

   1. Langan, E A
   2. Künstner, A
   3. Miodovnik, M
   4. Zillikens, D
   5. Thaçi, D
   6. Baines, J F
   7. Ibrahim, S M

   2019 - Forschungsinformationssystem des UKE
6. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

   1. Körber, A
   2. Thaçi, D
   3. von Kiedrowski, R
   4. Bachhuber, T
   5. Melzer, N
   6. Kasparek, T
   7. Kraehn-Senftleben, G

   2018 - Forschungsinformationssystem des UKE
7. The role of the microbiome in Psoriasis: moving from disease description to treatment selection?

   1. Langan, E A
   2. Griffiths, C E M
   3. Solbach, W
   4. Knobloch, J K
   5. Zillikens, D
   6. Thaçi, D

   2018 - Forschungsinformationssystem des UKE
8. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management

   1. Augustin, M
   2. Langenbruch, A
   3. Gutknecht, M
   4. Reich, K
   5. Körber, A
   6. Maaßen, D
   7. Mrowietz, U

   2018 - Forschungsinformationssystem des UKE
9. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic Treatments: results from the randomized controlled PRIME trial

   1. Sticherling, M
   2. Mrowietz, U
   3. Augustin, M
   4. Thaçi, D
   5. Melzer, N
   6. Hentschke, C
   7. Kneidl, J

   2017 - Forschungsinformationssystem des UKE
10. The German National Program on Psoriasis Health Care 2005-2015: Results and Experiences

    1. Augustin, M
    2. Eissing, L
    3. Langenbruch, A
    4. Enk, A
    5. Luger, T
    6. Maaßen, D
    7. Mrowietz, U

    2016 - Forschungsinformationssystem des UKE